Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study

Figure 1  Detailed process of personnel screening.

Figure 2 Forest plot. A: Forest plot of effect values of metabolic dysfunction-associated fatty liver disease (MASLD) on gynecomastia (GYN) by subgroups; B: Forest plot of MASLD on the overall impact value of GYN. ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; DBP: Diastolic blood pressure; DM: Diabetes mellitus; ETR: Estrogen to androgen ratio; E2: Estradiol; FBG: Fasting blood glucose; GGT: Gamma-glutamyltransferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; OR: Odds ratio; SBP: Systolic blood pressure; T: Testosterone; TC: Total cholesterol; TG: Triglycerides; UA: Uric acid; WC: Waist circumference.

Figure 3 Receiver operating characteristic curves for the occurrence of gynecomastia in patients with sex hormone-diagnosed metabolic dysfunction-associated fatty liver disease. ETR: Estrogen to androgen ratio; E2: Estradiol; ROC: Receiver operating characteristic.